Summary

The global cattle & porcine/swine reproductive diseases market is projected to reach USD 975.8 million by 2029 from USD 758.2 million in 2024 at a CAGR of 5.2%. Between January 2021 and August 2024, major players in this market adopted various strategies to expand their global presence and increase market share. These tactics include entering into strategic agreements, divestitures, expanding operations, and acquiring other companies. These efforts aim to enhance product portfolios, improve efficiency, and tap into new regional markets. The competitive landscape illustrates the industry's focus on meeting the rising demand for reproductive disease treatments in cattle and pigs, which is crucial for supporting the global livestock sector.

“The Pharmaceutical segment is expected to grow at the second highest CAGR in the cattle & porcine/swine reproductive diseases market.”
By product type, the pharmaceuticals segment represents the second highest CAGR in the cattle & porcine/swine reproductive diseases market. This is mainly due to some crucial factors. Advancements in the manufacturing of vaccines, such as the development of more effective formulations and sustainable production practices, have a great influence on market growth. The demand for the above-mentioned pharmaceutical products has increased due to the growing incidence of reproductive diseases in farm animals. The development of diagnostic tools supplements the application of vaccines and antibiotics, enabling timely and efficient disease detection. These two innovations, along with other improvements in their efficacy, have strongly supported the top market position of the pharmaceuticals segment.

“Bovine Viral Diarrhea (BVD) segment witnessed the second-highest CAGR in the cattle & porcine/swine reproductive diseases market.”
BVD is expected to be the second fastest-growing segment in terms of CAGR in the cattle & porcine/swine reproductive diseases market during the forecast period. Several factors have contributed to this growth: first, BVD affects several million cattle worldwide, resulting in marked economic losses due to reduced milk production and poor meat quality. Further, the various symptoms and complications of the disease necessitate a fitting response on the part of farmers and veterinarians. Increased regulatory focus, besides active initiatives by the industry for control and eradication of BVD, also drives the market. As such efforts start turning more concentrated and fruitful, solutions and services directed at overcoming BVD further amplify the demand for the same, thereby fueling market growth.

“The Porcine segment of the cattle & porcine/swine reproductive diseases market accounted for the second largest market share.”
Based on animal type, the porcine segment accounted for the second largest market share in the cattle & porcine/swine reproductive diseases market because of high economic impact of diseases like Porcine Reproductive and Respiratory Syndrome (PRRS) on pig farms drives significant spending on management and prevention. Second, the global rise in pork consumption and intensive pig farming practices increase the risk of disease spread, highlighting the need for effective disease control. Lastly, ongoing research works in vaccine and treatment options for porcine diseases boost market growth by offering better solutions to manage and prevent outbreaks. As pork production continues to expand, the focus on controlling reproductive diseases in pigs remains a high priority, further driving market demand.

“Veterinary hospitals and clinics segment of the cattle & porcine/swine reproductive diseases market is expected to witness the second highest CAGR.”
By end user, veterinary hospitals & clinics are expected to record the second-highest CAGR in the cattle & porcine/swine reproductive diseases market during the forecast period. Several factors contribute to such significant growth. Veterinary hospitals & clinics provide a place of advanced diagnostics and treatments essential for such specialized care, especially in reproductive problems in livestock. Due to this realization, farmers view these facilities as a source of expert medical services, thus making them seek accurate disease detection and a definite treatment plan. Besides this, increasing awareness concerning regular visits to veterinary institutes has also made farmers rely more on such institutions for preventive as well as curative purposes. The quality and customized services offered by veterinary clinics and hospitals contribute considerably to their popularity in the market.

“North America is expected to have the second highest CAGR in the cattle & porcine/swine reproductive diseases market, in the forecast period.”
In the North America region, the cattle & porcine/swine reproductive diseases market has grown significantly. The region's extensive cattle and pig farms drive a significant demand for reproductive health products and services. This demand is supported by well-established veterinary research institutions that foster innovation and advancements in disease management. Furthermore, strong government support and funding for animal health initiatives in countries such as the US and Canada enhance the market's robustness. The emphasis on boosting livestock productivity and upholding high standards of animal welfare also strengthens the region's position in the global market.


A breakdown of the primary participants (supply side) for the cattle & porcine/swine reproductive diseases market referred to for this report is provided below:
• By Company Type: Tier 1–45%, Tier 2–20%, and Tier 3–35%
• By Designation: C-level–35%, Director Level–25%, and Others–40%
• By Region: North America–40%, Europe–20%, Asia Pacific–25%, Latin America-10%, and Middle East & Africa-5%
A breakdown of the primary participants (demand side) for the cattle & porcine/swine reproductive diseases market refer to for the report is provided below:
• By End User Type: Cattle and Porcine Farms-55%, Veterinary Hospitals and Clinics-30%, and Veterinary Reference Laboratory-15%
• By Designation: Veterinarians-45%, Farm Owners-40%, and Laboratory Technicians-15%
• By Region: North America–34%, Europe–27%, Asia Pacific–23%, Latin America-9%, and Middle East & Africa-7%


Key Market Players:
The prominent players in the cattle & porcine/swine reproductive diseases market include Zoetis Inc. (US), Merck & Co., Inc. (US), Boehringer Ingelheim International GmBH (Germany), Virbac (France), Elanco Animal Health Incorporated (US), Vetoquinol S.A. (France), Ceva Santé Animale (France), Idexx Laboratories (US), Thermo Fisher Scientific Inc. (US), Biochek Smart Veterinary Diagnostics (Netherlands), Ring Biotechnology Co Ltd. (China), Sequent Scientific Limited (India), Hipra (Spain), Qiagen N.V. (Germany), Innovative Diagnostics (France), Colorado Serum Company (US), Indian Immunologicals Ltd (US), Refit Animal Care (India), Calier (US), Megacor Diagnostik GmBH (Austria), Vetanco (Brazil), Biogenesis Bago (Argentina), Advacare Pharma (US), Bio-X Diagnostics S.A. (Belgium), Pax Healthcare (India).

Research Coverage:
The market analysis examines the cattle & porcine/swine reproductive diseases market in numerous segments. It seeks to estimate the market size and growth potential across many segments, including product type, disease type, animal type, end user type and geography. The study also includes a detailed competitive analysis of the market's top competitors, as well as company profiles, significant insights about their product and business offerings, recent developments, and key market strategies.
Key Benefits of Buying the Report:
The study will assist industry leaders/new entrants in this market by providing information on the closest approximations of the cattle & porcine/swine reproductive diseases market and its segments. This research will assist stakeholders understand the competitive landscape, obtaining insights to better position their firms, and developing appropriate go-to-market strategies. The study will also assist stakeholders in understanding the market pulse and obtaining information on major market drivers, constraints, opportunities, and challenges.


This report provides insights into the following pointers:
 Analysis of key Drivers: Drivers (Rising demand for animal-derived food products, Increasing prevalence of reproductive health issues, Growing number of veterinary practitioner in developed markets, Increasing per capita income of farmers in developing countries), Restrains (Lack of awareness and knowledge among small-scale farmers), Opportunities (Advancements in veterinary healthcare, Untapped emerging markets), Challenges (Stringent regulatory guidelines for livestock industry) influencing the growth of the cattle & porcine/swine reproductive diseases market.
• Market Penetration: Comprehensive information on the product portfolios of the leading companies in the cattle & porcine/swine reproductive diseases market. The report breaks down the market by product type, disease type, animal type, end user type and region.
• Product Enhancement/Innovation: Detailed information about forthcoming trends and product launches in the cattle & porcine/swine reproductive diseases market.
• Market Development: Comprehensive data on attractive rising markets broken down by product type, disease type, animal type, end user type and region.
• Market Diversification: Comprehensive information on new products, expanding geographies, current advancements, and investments in the cattle & porcine/swine reproductive diseases market.
• Competitive Assessment: In-depth analysis of market share, growth strategies, product and service offerings, and capabilities of the main udder health products manufacturers.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 30
1.2.1 INCLUSIONS & EXCLUSIONS 30
1.2.2 MARKETS COVERED 31
1.2.3 YEARS CONSIDERED 32
1.2.4 CURRENCY CONSIDERED 32
1.3 MARKET STAKEHOLDERS 33
2 RESEARCH METHODOLOGY 34
2.1 RESEARCH APPROACH 34
2.1.1 SECONDARY DATA 34
2.1.1.1 Key data from secondary sources 36
2.1.2 PRIMARY DATA 37
2.1.2.1 Primary sources 37
2.1.2.2 Key data from primary sources 38
2.1.2.3 Key industry insights 39
2.2 MARKET SIZE ESTIMATION 41
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 46
2.4 MARKET SHARE ESTIMATION 47
2.4.1 STUDY ASSUMPTIONS 47
2.5 RISK ASSESSMENT 48
2.6 RESEARCH LIMITATIONS 48
2.6.1 METHODOLOGY-RELATED LIMITATIONS 48
2.6.2 SCOPE-RELATED LIMITATIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 55
4.1 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET OVERVIEW 55
4.2 EUROPE: CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET,
BY PRODUCT AND COUNTRY (2023) 56
4.3 REGIONAL MIX: CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET 57
4.4 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET:
GEOGRAPHICAL GROWTH OPPORTUNITIES 57
 
5 MARKET OVERVIEW 58
5.1 INTRODUCTION 58
5.2 MARKET DYNAMICS 58
5.2.1 DRIVERS 59
5.2.1.1 Growing demand for animal−derived food products 59
5.2.1.2 Increasing prevalence of reproductive health issues 61
5.2.1.3 Rising number of veterinary practitioners in developed markets 62
5.2.1.4 Increasing per capita income of farmers in emerging markets 63
5.2.2 RESTRAINTS 64
5.2.2.1 Limited awareness & education among small-scale farmers 64
5.2.3 OPPORTUNITIES 64
5.2.3.1 Advancements in veterinary healthcare 64
5.2.3.2 High growth potential of emerging economies 65
5.2.4 CHALLENGES 65
5.2.4.1 Stringent regulatory guidelines for livestock industry 65
5.3 INDUSTRY TRENDS 66
5.3.1 INCREASING ADOPTION OF VACCINATION PROGRAMS 66
5.3.2 EMPHASIS ON SUSTAINABLE PRACTICES 66
5.4 TECHNOLOGY ANALYSIS 67
5.4.1 KEY TECHNOLOGIES 67
5.4.1.1 Vaccination technologies 67
5.4.1.2 Diagnostic tools 67
5.4.2 COMPLEMENTARY TECHNOLOGIES 67
5.4.2.1 Genomic selection & breeding 68
5.4.2.2 Precision livestock farming 68
5.4.3 ADJACENT TECHNOLOGIES 69
5.4.3.1 Nutritional supplements & additives 69
5.4.3.2 Integration of livestock management software 69
5.5 PORTER’S FIVE FORCES ANALYSIS 70
5.5.1 THREAT OF NEW ENTRANTS 70
5.5.2 BARGAINING POWER OF SUPPLIERS 71
5.5.3 BARGAINING POWER OF BUYERS 71
5.5.4 THREAT OF SUBSTITUTES 71
5.5.5 COMPETITIVE RIVALRY 72
5.6 KEY STAKEHOLDERS AND BUYING CRITERIA 74
5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 74
5.6.2 BUYING CRITERIA 74
5.7 REGULATORY LANDSCAPE 75
5.7.1 REGULATORY ANALYSIS 75
5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 77
 
5.8 PATENT ANALYSIS 80
5.8.1 PATENT PUBLICATION TRENDS FOR CATTLE & PORCINE
REPRODUCTIVE DISEASES MARKET 80
5.8.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 81
5.9 TRADE ANALYSIS 84
5.9.1 TRADE ANALYSIS FOR CATTLE & PORCINE REPRODUCTIVE PRODUCTS 84
5.10 PRICING ANALYSIS 85
5.10.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY TYPE 85
5.10.2 AVERAGE SELLING PRICE TREND OF CATTLE & PORCINE REPRODUCTIVE HEALTH PRODUCTS, BY REGION 86
5.11 REIMBURSEMENT ANALYSIS 87
5.12 KEY CONFERENCES AND EVENTS 88
5.13 UNMET NEEDS/END-USER EXPECTATIONS IN CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET 89
5.14 IMPACT OF GEN AI ON CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET 90
5.15 ECOSYSTEM ANALYSIS 91
5.16 CASE STUDY ANALYSIS 93
5.16.1 INNOVATION IN BOVINE REPRODUCTIVE DISEASE VACCINATION 93
5.16.2 TECH-DRIVEN SOLUTIONS FOR LIVESTOCK REPRODUCTIVE HEALTH 93
5.16.3 INTEGRATED HEALTH SOLUTIONS FOR CATTLE REPRODUCTIVE HEALTH 94
5.17 SUPPLY CHAIN ANALYSIS 95
5.18 VALUE CHAIN ANALYSIS 96
5.19 ADJACENT MARKETS FOR CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET 97
5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESSES 98
5.21 INVESTMENT & FUNDING SCENARIO 98
6 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY PRODUCT 99
6.1 INTRODUCTION 100
6.2 DIAGNOSTICS 100
6.2.1 ELISA TEST KITS 103
6.2.1.1 Advancements in biotechnology to drive market 103
6.2.2 PCR TEST KITS 105
6.2.2.1 Increasing adoption of on-farm PCR testing solutions to fuel uptake 105
6.2.3 RAPID ANTIGEN TEST KITS 107
6.2.3.1 Growing demand for reliable solutions with quick turnaround
time to drive market 107
6.2.4 OTHER DIAGNOSTIC PRODUCTS 109
6.3 PHARMACEUTICALS 111
6.3.1 VACCINES 113
6.3.1.1 Enhancements in vaccine technology & formulation to drive market 113
6.3.2 ANTIBIOTICS 115
6.3.2.1 Convenient purchase options and long-term benefits to
boost demand 115
6.3.3 HORMONAL THERAPY 117
6.3.3.1 Ability to mimic natural hormones to boost demand 117
6.3.4 OTHER PHARMACEUTICAL PRODUCTS 119
6.4 SUPPLEMENTS 121
6.4.1 VITAMINS & MINERALS 123
6.4.1.1 Rising focus on nutrition and reproductive health to
support market growth 123
6.4.2 OTHER SUPPLEMENTS 125
7 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY DISEASE TYPE 127
7.1 INTRODUCTION 128
7.2 LEPTOSPIROSIS 129
7.2.1 RISING CASES DUE TO CLIMATE CHANGE TO DRIVE MARKET 129
7.3 BRUCELLOSIS 131
7.3.1 IMPACT ON LIVESTOCK PRODUCTIVITY DUE TO CONTAGIOUS NATURE TO SUPPORT MARKET GROWTH 131
7.4 PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) 133
7.4.1 INCREASING PORK CONSUMPTION TO PROPEL MARKET 133
7.5 BOVINE VIRAL DIARRHEA (BVD) 135
7.5.1 HIGH MORBIDITY RATE TO DRIVE MARKET 135
7.6 VIBRIOSIS 137
7.6.1 GROWING DEMAND FOR HIGH-YIELDING LIVESTOCK TO
SUPPORT MARKET GROWTH 137
7.7 OTHER CATTLE & PORCINE DISEASES 139
8 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY ANIMAL TYPE 141
8.1 INTRODUCTION 142
8.2 CATTLE 142
8.2.1 DAIRY CATTLE 145
8.2.1.1 Increasing demand for milk & dairy products to boost demand 145
8.2.2 BEEF CATTLE 147
8.2.2.1 Increasing demand for beef to drive market 147
8.3 PORCINE 149
9 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY END USER 151
9.1 INTRODUCTION 152
9.2 CATTLE & PORCINE FARMS 152
9.2.1 GROWING DEMAND FOR MEAT & DAIRY PRODUCTS TO DRIVE MARKET 152
9.3 VETERINARY HOSPITALS & CLINICS 154
9.3.1 INCREASING VETERINARY HEALTHCARE INVESTMENTS IN EMERGING MARKETS TO BOOST DEMAND 154
9.4 VETERINARY REFERENCE LABORATORIES 156
9.4.1 INCREASING TECHNOLOGICAL ADVANCEMENTS IN VETERINARY DIAGNOSTICS TO SUPPORT MARKET GROWTH 156
10 CATTLE & PORCINE REPRODUCTIVE DISEASES MARKET, BY REGION 158
10.1 INTRODUCTION 159
10.2 NORTH AMERICA 160
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 160
10.2.2 US 164
10.2.2.1 Large-scale livestock operations and advanced veterinary
practices to drive market 164
10.2.3 CANADA 167
10.2.3.1 Rising concerns about food safety & quality to fuel market 167
10.3 EUROPE 171
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 171
10.3.2 GERMANY 176
10.3.2.1 Adoption of advanced technologies for milk & dairy products
to drive market 176
10.3.3 UK 180
10.3.3.1 Favorable government support for animal healthcare
to boost demand 180
10.3.4 FRANCE 183
10.3.4.1 Growth in veterinary & healthcare industries to drive market 183
10.3.5 ITALY 186
10.3.5.1 Growing focus on swine & dairy farming to fuel uptake 186
10.3.6 SWITZERLAND 190
10.3.6.1 Technologically advanced agriculture sector to fuel market 190
10.3.7 SPAIN 193
10.3.7.1 High exports of meat & milk to contribute to market growth 193
10.3.8 REST OF EUROPE 197
10.4 ASIA PACIFIC 200
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 200
10.4.2 JAPAN 204
10.4.2.1 Rising focus on dairy industry to drive market 204
10.4.3 CHINA 207
10.4.3.1 Rising prevalence of infectious diseases in livestock to propel market 207
10.4.4 INDIA 211
10.4.4.1 Expanding cattle population to boost demand 211
10.4.5 AUSTRALIA 215
10.4.5.1 Emphasis on sustainable & systematic farming practices to
support market growth 215
10.4.6 SOUTH KOREA 218
10.4.6.1 Rise in pork & beef consumption to drive market 218
10.4.7 REST OF ASIA PACIFIC 221
 
10.5 LATIN AMERICA 224
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 225
10.5.2 BRAZIL 228
10.5.2.1 Growing demand for veterinary services to fuel uptake 228
10.5.3 MEXICO 231
10.5.3.1 Improvements in animal welfare to support market growth 231
10.5.4 REST OF LATIN AMERICA 235
10.6 MIDDLE EAST & AFRICA 238
10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 238
10.6.2 GCC COUNTRIES 242
10.6.2.1 Growing demand for dairy to fuel market 242
10.6.3 REST OF MIDDLE EAST & AFRICA 245
11 COMPETITIVE LANDSCAPE 248
11.1 OVERVIEW 248
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 248
11.3 REVENUE ANALYSIS 250
11.4 MARKET SHARE ANALYSIS 251
11.4.1 RANKING OF KEY MARKET PLAYERS 253
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 253
11.5.1 STARS 253
11.5.2 EMERGING LEADERS 253
11.5.3 PERVASIVE PLAYERS 254
11.5.4 PARTICIPANTS 254
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 255
11.5.5.1 Company footprint 255
11.5.5.2 Product footprint 256
11.5.5.3 Disease type footprint 257
11.5.5.4 Animal type footprint 258
11.5.5.5 End-user footprint 259
11.5.5.6 Region footprint 260
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 261
11.6.1 PROGRESSIVE COMPANIES 261
11.6.2 DYNAMIC COMPANIES 261
11.6.3 STARTING BLOCKS 261
11.6.4 RESPONSIVE COMPANIES 261
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 263
11.7 COMPANY VALUATION & FINANCIAL METRICS 265
11.7.1 COMPANY VALUATION 265
11.7.2 FINANCIAL METRICS 265
11.8 BRAND/PRODUCT COMPARISON 266
11.9 R&D EXPENDITURE OF KEY PLAYERS 266
11.10 COMPETITIVE SCENARIO 267
11.10.1 PRODUCT APPROVALS/LAUNCHES 267
11.10.2 DEALS 267
11.10.3 EXPANSIONS 268
11.10.4 OTHER DEVELOPMENTS 269
12 COMPANY PROFILES 270
12.1 KEY PLAYERS 270
12.1.1 ZOETIS INC. 270
12.1.1.1 Business overview 270
12.1.1.2 Products offered 271
12.1.1.3 Recent developments 272
12.1.1.3.1 Deals 272
12.1.1.3.2 Expansions 273
12.1.1.3.3 Other developments 273
12.1.1.4 MnM view 274
12.1.1.4.1 Key strengths 274
12.1.1.4.2 Strategic choices 274
12.1.1.4.3 Weaknesses & competitive threats 274
12.1.2 MERCK & CO., INC. 275
12.1.2.1 Business overview 275
12.1.2.2 Products offered 277
12.1.2.3 Recent developments 277
12.1.2.3.1 Deals 277
12.1.2.3.2 Other developments 278
12.1.2.4 MnM view 278
12.1.2.4.1 Key strengths 278
12.1.2.4.2 Strategic choices 278
12.1.2.4.3 Weaknesses & competitive threats 278
12.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 279
12.1.3.1 Business overview 279
12.1.3.2 Products offered 280
12.1.3.3 Recent developments 281
12.1.3.3.1 Product launches 281
12.1.3.4 MnM view 281
12.1.3.4.1 Key strengths 281
12.1.3.4.2 Strategic choices 282
12.1.3.4.3 Weaknesses & competitive threats 282
12.1.4 VIRBAC 283
12.1.4.1 Business overview 283
12.1.4.2 Products offered 284
12.1.4.3 Recent developments 285
12.1.4.3.1 Deals 285
12.1.4.3.2 Expansions 285
12.1.4.4 MnM view 286
12.1.4.4.1 Key strengths 286
12.1.4.4.2 Strategic choices 286
12.1.4.4.3 Weaknesses & competitive threats 286
12.1.5 ELANCO ANIMAL HEALTH INCORPORATED 287
12.1.5.1 Business overview 287
12.1.5.2 Products offered 288
12.1.5.3 Recent developments 289
12.1.5.3.1 Deals 289
12.1.5.3.2 Expansions 289
12.1.5.4 MnM view 289
12.1.5.4.1 Key strengths 289
12.1.5.4.2 Strategic choices 290
12.1.5.4.3 Weaknesses & competitive threats 290
12.1.6 VETOQUINOL S.A. 291
12.1.6.1 Business overview 291
12.1.6.2 Products offered 293
12.1.7 CEVA SANTÉ ANIMALE 294
12.1.7.1 Business overview 294
12.1.7.2 Products offered 294
12.1.7.3 Recent developments 295
12.1.7.3.1 Deals 295
12.1.8 IDEXX LABORATORIES, INC. 296
12.1.8.1 Business overview 296
12.1.8.2 Products offered 297
12.1.8.3 Recent developments 298
12.1.8.3.1 Other developments 298
12.1.9 THERMO FISHER SCIENTIFIC INC. 299
12.1.9.1 Business overview 299
12.1.9.2 Products offered 301
12.1.10 BIOCHEK SMART VETERINARY DIAGNOSTICS 302
12.1.10.1 Business overview 302
12.1.10.2 Products offered 302
12.1.10.3 Recent developments 303
12.1.10.3.1 Expansions 303
12.1.11 RING BIOTECHNOLOGY CO LTD. 304
12.1.11.1 Business overview 304
12.1.11.2 Products offered 304
12.1.11.3 Recent developments 305
12.1.11.3.1 Product launches & approvals 305
12.1.12 SEQUENT SCIENTIFIC LIMITED 306
12.1.12.1 Business overview 306
12.1.12.2 Products offered 307
12.1.13 HIPRA 308
12.1.13.1 Business overview 308
12.1.13.2 Products offered 308
12.1.14 QIAGEN N.V. 309
12.1.14.1 Business overview 309
12.1.14.2 Products offered 310
12.1.15 INNOVATIVE DIAGNOSTICS 311
12.1.15.1 Business overview 311
12.1.15.2 Products offered 311
12.1.15.3 Recent developments 312
12.1.15.3.1 Other developments 312
12.2 OTHER PLAYERS 313
12.2.1 COLORADO SERUM COMPANY 313
12.2.2 INDIAN IMMUNOLOGICALS LTD. 314
12.2.3 REFIT ANIMAL CARE 315
12.2.4 CALIER 316
12.2.5 MEGACOR DIAGNOSTIK GMBH 317
12.2.6 VETANCO 318
12.2.7 BIOGENESIS BAGO 319
12.2.8 ADVACARE PHARMA 320
12.2.9 BIO-X DIAGNOSTICS S.A. 321
12.2.10 PAX HEALTHCARE 322
13 APPENDIX 323
13.1 DISCUSSION GUIDE 323
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 330
13.3 CUSTOMIZATION OPTIONS 332
13.4 RELATED REPORTS 332
13.5 AUTHOR DETAILS 333